Cobra Biologics Ltd and NEUWAY Pharma GmbH have announced the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection.
The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.
Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”
Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”